Letter to Editor: Chloroquine/Hydroxychloroquine and SARS-CoV 2; Lessons from Case-Control Studies

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

GHAZVINI K.; KEIKHA M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: IRANIAN JOURNAL OF VIROLOGY Year:2020 | Volume:14 | Issue:2 Page(s): 38-41

Download Full-Text

View:

132

Download:

113

Cites:

Information Journal Paper

Title

Letter to Editor: Chloroquine/Hydroxychloroquine and SARS-CoV 2; Lessons from Case-Control Studies

Author(s)

GHAZVINI K. | KEIKHA M. | Issue Writer Certificate

Keywords

Chloroquine

Hydroxychloroquine

SARS-CoV 2

COVID-19

Abstract

D ear Editor. In December 2019, a novel viral pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV 2) was emerged in Wuhan, Hubei Province, China [1]. We are lives in global pandemic of coronavirus disease 2019 (COVID‐ 19); However, we have limited therapeutic agents for treatment of COVID-19 and reduction of mortality caused by this virus; there is no FDA approved option against SARS-CoV 2 which is global concern [2]. According to review of the literatures, there are suggested several drugs including Remdesivir, Favipiravir, Ribavirin, Interferons, Lopinavir/ritonavir, Oseltamivir, Chloroquine, hydroxyChloroquine, and azithromycin, Convalescent plasma, Herbal medications, nonsteroidal antiinflammatory drugs (NSAIDs), Mycophenolic acid, Monoclonal or polyclonal antibodies, and, Angiotensin‐ converting enzyme 2 gene‐ based peptides for combating with SARS-CoV 2 [3]; but there is no conclusive evidence for efficacy and safety of these therapeutic agents against COVID-19 [4-5]. . .

Cites

No record.

References

Cite

APA: Copy

GHAZVINI, K., & KEIKHA, M.. (2020). Letter to Editor: Chloroquine/Hydroxychloroquine and SARS-CoV 2; Lessons from Case-Control Studies. IRANIAN JOURNAL OF VIROLOGY, 14(2), 38-41. SID. https://sid.ir/paper/764901/en

Vancouver: Copy

GHAZVINI K., KEIKHA M.. Letter to Editor: Chloroquine/Hydroxychloroquine and SARS-CoV 2; Lessons from Case-Control Studies. IRANIAN JOURNAL OF VIROLOGY[Internet]. 2020;14(2):38-41. Available from: https://sid.ir/paper/764901/en

IEEE: Copy

K. GHAZVINI, and M. KEIKHA, “Letter to Editor: Chloroquine/Hydroxychloroquine and SARS-CoV 2; Lessons from Case-Control Studies,” IRANIAN JOURNAL OF VIROLOGY, vol. 14, no. 2, pp. 38–41, 2020, [Online]. Available: https://sid.ir/paper/764901/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops